scholarly journals Enterococcal Bloodstream Infection After Hematopoietic Stem Cell Transplant: Experience of a Center With a Low Prevalence of Vancomycin-Resistant Enterococci

2012 ◽  
Vol 55 (12) ◽  
pp. 1744-1744 ◽  
Author(s):  
M. Mikulska ◽  
V. Del Bono ◽  
A. M. Raiola ◽  
A. Signori ◽  
R. Prinapori ◽  
...  
Keyword(s):  
Stem Cell ◽  
Bloodstream Infection ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Vancomycin Resistant Enterococci ◽  
Vancomycin Resistant ◽  
Low Prevalence

Citrobacter braakii CLABSI in a hematopoietic stem cell transplant patient

2021 ◽  
pp. 107815522110014
Author(s):  
Eris Tollkuci ◽  
Rebecca Myers
Keyword(s):  
Stem Cell ◽  
Bloodstream Infection ◽  
Hematopoietic Stem Cell ◽  
Health Care Providers ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Care Providers ◽  
Hematopoietic Stem ◽  
Important Relationship

Introduction Citrobacter bacteria are gram-negative anaerobic bacilli commonly found in water, soil, food, and the intestinal tracts of animals and humans. Patients at highest risk of these nosocomial infections include neonates and adults who are ≥65 years of age, debilitated, or immunocompromised. Citrobacter braakii ( C. braakii), specifically, has been reported to cause sepsis in immunocompromised patients. Herein, we describe a case of an allogeneic stem cell transplant (SCT) adult patient with C. braakii bloodstream infection. Case Report We report our experience managing a central line-associated bloodstream infection (CLABSI) due to C. braakii in an allogeneic SCT patient. Management and Outcomes: Our patient was initially managed with cefepime. The central venous catheter (CVC) was removed. Blood cultures cleared 24 hours after antibiotic initiation. Therapy was transitioned to oral levofloxacin once susceptibilities resulted. Discussion The course of this patient highlights the important relationship between an unusual pathogen, C. braakii, in an immunocompromised allogeneic SCT patient. In our case, the source of the bacteremia was most likely a CLABSI given the positive catheter tip cultures. Although this report describes the successful utilization of cefepime and levofloxacin in the treatment of C. braakii infection, caution should be exercised when choosing empiric antimicrobial therapy as AmpC resistance. This clinical scenario can aid health care providers in making informed treatment decisions when faced with patients diagnosed with this relatively uncommon pathogen. Further reports should be published to determine C. braakii bacteremia management in hematopoietic stem cell transplant patients.

scholarly journals The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients

2014 ◽  
Vol 55 (12) ◽  
pp. 2858-2865 ◽  
Author(s):  
Michael J. Satlin ◽  
Rosemary Soave ◽  
Alexandra C. Racanelli ◽  
Tsiporah B. Shore ◽  
Koen van Besien ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Stem ◽  
Vancomycin Resistant ◽  
Enterococcal Bacteremia

scholarly journals Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 3 ◽  
Author(s):  
Esther Benamu ◽  
Stanley Deresinski
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
The United States ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Increased Risk ◽  
Vancomycin Resistant ◽  
Clinical Questions

Vancomycin-resistantenterococcus(VRE) is now one of the leading causes of nosocomial infections in the United States. Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of VRE colonization and infection. VRE has emerged as a major cause of bacteremia in this population, raising important clinical questions regarding the role and impact of VRE colonization and infection in HSCT outcomes as well as the optimal means of prevention and treatment. We review here the published literature and scientific advances addressing these thorny issues and provide a rational framework for their approach.

Sign in / Sign up

Export Citation Format

Share Document